Harmony Biosciences Holdings (HRMY) Capital Expenditures (2019 - 2025)

Harmony Biosciences Holdings has disclosed Capital Expenditures across 6 years of filings, most recently posting $107000.0 for Q4 2025.

• Capital Expenditures for Q4 2025 came in at $107000.0, down 79.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $310000.0 (down 73.11% YoY), and the FY2025 annual result was $310000.0, down 73.11% from the prior year.
• Capital Expenditures came in at $107000.0 for Q4 2025 at Harmony Biosciences Holdings, up from $71000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $632000.0 in Q2 2024 to a low of $3000.0 in Q3 2024.
• The 5-year median for Capital Expenditures is $86000.0 (2022), against an average of $136000.0.
• Peak annual rise in Capital Expenditures reached 2460.0% in 2025, while the deepest fall reached 99.37% in 2025.
• Harmony Biosciences Holdings' Capital Expenditures stood at $93000.0 in 2021, then dropped by 7.53% to $86000.0 in 2022, then climbed by 24.42% to $107000.0 in 2023, then soared by 379.44% to $513000.0 in 2024, then tumbled by 79.14% to $107000.0 in 2025.
• The last three Capital Expenditures figures came in at $107000.0 (Q4 2025), $71000.0 (Q3 2025), and $4000.0 (Q2 2025), per Business Quant data.